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S U M M A R Y
Objectives: To estimate the prevalence and determine the clinical presentation of risk factors of hepatitis
C virus (HCV) among HIV-infected patients in Bissau, Guinea-Bissau.
Methods: In this cross-sectional study, we included individuals who had a routine blood analysis
performed during the period April 28 to September 30, 2011. Patient samples were tested for HCV
antibodies (anti-HCV) with a chemiluminescence test (Architect, Abbott, USA) and INNO-LIA HCV Score
(Innogenetics, Belgium). HCV viral load and genotype were analyzed using an in-house real-time PCR
method.
Results: In total, 576 patients were included (417 HIV-1, 104 HIV-2, and 55 HIV-1/2). Ten (1.7%) patients
were anti-HCV-positive and eight (1.4%) patients had detectable HCV RNA; all were genotype 2. In a
multivariable logistic regression analysis, age >50 years was associated with anti-HCV reactivity
(p < 0.01). No subjective symptoms or objective signs were more prevalent among patients with
detectable HCV RNA compared to patients without detectable HCV RNA. Biochemically, detectable HCV
RNA was associated with elevated amylase (83.3% vs. 38.6%, p = 0.03), but not with the liver enzymes
alanine aminotransferase and aspartate aminotransferase.
Conclusions: The prevalence of anti-HCV was low and comparable to similar settings, and genotype
analysis conﬁrmed the presence of genotype 2 in West Africa.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Approximately 34 million people are infected with HIV
worldwide, of whom one to two million have an HIV-2 infection,
an epidemic mainly conﬁned to West Africa.1,2 The West African§ Results of this study were presented as a poster at the 30th Annual Meeting of
the Nordic Society of Clinical Microbiology and Infectious Diseases, Aarhus,
Denmark, September 5–8, 2013.
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http://dx.doi.org/10.1016/j.ijid.2014.06.007
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).country Guinea-Bissau is currently experiencing a rise in HIV-1
prevalence and at the same time holds the world’s highest
prevalence of HIV-2.3 An estimated 170 million people are
chronically infected with hepatitis C virus (HCV) and more than
three million are infected annually.4 Based on the RNA sequence
homology, HCV has been classiﬁed into six major genotypes and
several subtypes; genotype 2 has previously been found in Guinea-
Bissau.5 HCV shares a route of transmission with HIV, and the
greatest risk of transmission occurs with direct percutaneous
exposure to infectious blood.6 HCV may also be transmitted
sexually, but the risk is considered relatively low.7 Although HCV is
prevalent in Sub-Saharan Africa, the predominant modes ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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performed due to resource constraints and unreliable serological
tests, the lack of molecular (PCR) based tests,9 and no available
HCV-speciﬁc antiviral therapy.10 Since reliable HCV tests are not
available for widespread screening in low-resource settings,
physicians must often rely on clinical intuition. Unfortunately,
data on symptoms and objective signs of chronic HCV infection in
Sub-Saharan Africa are scarce.
Almost ﬁve million people are co-infected with both HIV and
HCV,11 but the prevalence of HIV/HCV co-infection varies
geographically; in Sub-Saharan Africa the prevalence of HCV
among HIV-infected patients ranges between 0% and 22%.12 The
rate of spontaneous HCV clearance is lower among HIV co-infected
patients than among individuals without HIV infection.13 In
regions with increasing availability of antiretroviral treatment
(ART), life expectancy for HIV-infected patients is rising; thus,
HCV-related morbidity may become more important.12,14 Certain-
ly, HIV/HCV co-infection has been found to be associated with an
increased incidence of end-stage liver disease and a poorer survival
than for HCV infection alone.15 This is probably due to a more rapid
liver disease progression and liver damage among severely
immunosuppressed patients infected with HIV.16 Furthermore,
HCV infection increases the frequency of hepatotoxicity of ART and
may affect the physicians’ choice of ART regimen.17 The risk
factors, demographic and clinical features of HIV and HCV co-
infection in Sub-Saharan Africa are poorly studied and a better
understanding is necessary to develop clinical strategies.9,18 In this
study we aimed to estimate the prevalence, risk factors, and
clinical presentation of HCV among HIV-infected patients in
Bissau, Guinea-Bissau.
2. Methods
2.1. Study design and sample collection
The study was conducted at the outpatient ART centre of the
Hospital National Sima˜o Mendes (HNSM) in Bissau, in collabora-
tion with the Bandim Health Project and the National HIV
Programme. The outpatient ART centre of HNSM is the largest
ART centre in Guinea-Bissau, providing care for citizens of Bissau
and operating as a reference centre for the other HIV clinics in the
country. At the ﬁrst visit to the clinic, HIV testing is performed and
basic demographic information is collected. Blood sampling of
patients is usually performed at the clinic the following day and
subsequently whenever the physicians request analyses, according
to national guidelines. Blood samples are sent to the National
Public Health Laboratory for CD4 cell count analyses on a daily
basis. Routines at the HIV clinic have been described previously.19
All HIV-infected patients aged >15 years attending for routine
blood analysis at the HIV clinic at HNSM and who provided enough
blood to perform hepatitis serological analyses (>0.5 ml plasma)
were consequently enrolled in the study from April 28 to
September 30, 2011. No patients were excluded. Questionnaires
were used to collect demographic information, symptoms, and
potential risk behaviours and were completed on the day of blood
sampling; physical examinations were carried out immediately
after the interview. Patients were asked about symptoms of liver
disease (nausea, vomiting, abdominal pain, skin itching, dimin-
ished libido, and diminished appetite) and risk factors (number of
sexual partners, age at ﬁrst marriage, ever bought/sold sexual
services, use of condoms, circumcision, previous surgery, dentist
treatment, previous blood transfusion, tattoo, traditional scariﬁca-
tions, ever been to prison/arrest, injection drug use, variola
vaccination scar, and BCG vaccination scar). The physical
examinations were performed with a focus on objective signs of
liver disease (icterus, dilated abdominal veins, gynaecomastia,ascites, enlarged liver, tenderness beneath right curvature, axillary
alopecia, and oedema).
2.2. HIV testing
Screening for HIV was done with a rapid test in the clinic
(Determine HIV-1/2 Assay; Abbott Laboratories). HIV type
discrimination was performed with Genie III HIV-1/HIV-2 (Bio-
Rad, Steenvoorde, France).20
2.3. HCV serology
Plasma samples were tested for hepatitis B surface antigen
(HBsAg) and HCV antibodies (anti-HCV) at the Department of
Clinical Immunology, Aarhus University Hospital, Denmark using
commercially available chemiluminescence assays (anti-HCV and
HBsAg, Architect; Abbott Laboratories, Abbott Park, IL, USA). All
anti-HCV reactive samples were tested for HCV RNA. Samples
testing anti-HCV reactive but HCV RNA-negative were subse-
quently conﬁrmed with INNO-LIA HCV Score (Innogenetics,
Belgium), which was considered conclusive in the case of
mismatch with the chemiluminescence test.
2.4. HCV virology
HCV quantiﬁcation was performed at the Department of
Clinical Biochemistry, Section of Molecular Diagnostics, Aalborg
University Hospital, Denmark. Samples were analyzed using in-
house real-time PCR methods. Primers from the 50 non-coding
untranslated region (UTR) of the virus were used.21 The limit of
quantiﬁcation was 20 IU/ml. HCV genotyping was carried out with
genotype-speciﬁc primer pairs, and a common beacon probe from
the 50 non-coding UTR of the genome was used.22
2.5. Statistical analysis
We analyzed the data using the Chi-square test for categorical
variables. Continuous variables were compared using the two-
sample t-test (normal distribution) or Wilcoxon rank sum test
(non-normal distribution). Groups with a sample size of 5 were
compared using Fisher’s exact test. Abnormal biochemical and
haematological values were deﬁned in accordance with reference
levels used at HNSM. For the analysis of risk factors for anti-HCV,
we used logistic regression and included variables associated with
anti-HCV in the Chi-square test, t-test, and Wilcoxon rank sum test
(p < 0.10). A p-value below 0.05 was considered signiﬁcant. Data
were analyzed using Stata IC 11.0 (StataCorp LC, College Station,
TX, USA).
2.6. Ethics
All patients provided voluntary signed informed consent, or a
ﬁngerprint if illiterate, prior to inclusion. Patients consented to
donate a blood sample and to the use of data provided for this
study. The Danish ethics committee gave consultative approval
(case number 1010050) and the study was ﬁnally approved by
UCEPS, the National Ethics Committee of Guinea-Bissau (N. ref.
016/CNES/2011).
3. Results
3.1. Patient characteristics
During the study period, 930 patients had a blood sample taken
for analyses and 576 patients provided sufﬁcient blood to be
included in the study. The HIV type discriminatory test revealed
Table 1
Characteristics of the 576 HIV-infected patients included in the study
Variable Anti-HCV-negative Anti-HCV-positive p-Value
n = 566 (98.3%) n = 10 (1.7%)
Sex (%) 0.44
Male 178/564 (31.6) 2/10 (20.0)
Female 386/564 (68.4) 8/10 (80.0)
Age stratiﬁcation (%) <0.01
30 years 131/539 (24.3) 0/10 (0.0)
30–49 years 315/539 (58.4) 4/10 (40.0)
50 years 93/539 (17.3) 6/10 (60.0)
HIV-type (%) 0.98
HIV-1 410/56 (72.4) 7/10 (70.0)
HIV-2 102/566 (18.0) 2/10 (20.0)
HIV-1/2 54/566 (9.5) 1/10 (10.0)
CD4 cell count (%) 0.12
200 cells/ml 181/548 (33.0) 3/9 (33.3)
201–350 cells/ml 152/548 (27.7) 5/9 (55.6)
>350 cells/ml 215/548 (39.2) 1/9 (11.1)
Nutritional status (%) 0.49
BMI 18.5 kg/m2 168/556 (30.2) 2/10 (20.0)
BMI >18.5 kg/m2 388/556 (69.8) 8/10 (80.0)
Treatment status (%) 0.08
Naı¨ve 272/566 (48.1) 2/10 (20.0)
On treatment 294/566 (51.9) 8/10 (80.0)
Ethnic group (%) 0.29
Mandinka 59/565 (10.4) 0/0 (0.0)
Fula 105/565 (18.6) 0/0 (0.0)
Papel 68/565 (12.0) 2/10 (20.0)
Mancanha 55/565 (9.7) 1/10 (10.0)
Balanta 129/565 (22.8) 4/10 (40.0)
Mandjako 40/565 (7.1) 2/10 (20.0)
Other 109/565 (19.3) 1/10 (10.0)
HCV, hepatitis C virus; BMI, body mass index.
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infected, and 55 (9.5%) were HIV-1/2 dually infected. Three
hundred and ninety-four patients (68.4%) were female. The median
age at the time of inclusion was 38 years (interquartile range (IQR)
31–47 years). Within 30 days of the interview, the CD4 cell count
was available for 556 patients (96.5%); the median CD4 cell count
was 286 cells/ml (IQR 164–434 cells/ml). Three hundred and two
patients (52.4%) received ART. Overall 191 patients (33.2%) had
been diagnosed with HIV within 30 days of inclusion into our study
and only two of the newly diagnosed patients had initiated ART.
The most frequently used ART combination at inclusion was
zidovudine, lamivudine, and nevirapine (43.3%), followed by
zidovudine, lamivudine, and efavirenz (15.1%) and zidovudine,
lamivudine, and ritonavir-boosted indinavir (14.8%). The median
duration of ART was 514 days (IQR 249–876 days).
3.2. HCV serology, viral load, and genotyping
Twenty-four patients (4.2%) were reactive for anti-HCV in the
chemiluminescence test (Figure 1). Anti-HCV-positive and HCV
RNA-negative samples had a conﬁrmatory anti-HCV test per-
formed (HCV INNO-LIA Score) in which 2/16 (12.5%) were reactive;
the adjusted anti-HCV prevalence was 10/576 (1.7%) and the
speciﬁcity of the chemiluminescence test was 97.5%. HCV RNA was
detected in 8/24 samples (33.3%); HCV RNA prevalence was 1.4%.
HCV RNA ranged between 65  103 and 7800  103 IU/ml and all
were genotype 2. Only one patient was co-infected with hepatitis B
virus (HBsAg-positive) and HCV. This patient was also dually
infected with both HIV-1 and HIV-2.
3.3. Characteristics and risk factors of HCV infection
Patients with a past or current HCV infection were compared to
uninfected patients (Table 1). The median age was signiﬁcantly
higher among anti-HCV-positive patients (52 years, IQR 43–54)
compared to anti-HCV-negative patients (38 years, IQR 31–46;Anti-HCV screening
N=576 (100.0%)
HCV RNA,  Rea l-tim e PC R, in house method
n=24  (4.2 %)
Anti-HCV con firmatory test
n= 16 (2.8 %)
Reactive
n=24  (4.2 %)
Nonre active
n=552  (95.8 %)
Detec ted
(Scree ning test
true positive)
n=8  (1.4 %)
Not detec ted
n=16  (2.8 %)
Negative
(Scree ning test
false positive)
n=9 (1.6 %)
Indetermi nate
(Scree ning test
false positive)
n=5 (0.9 %)
Positive
(Scree ning test
true positive)
n=2 (0.3 %)
Figure 1. Hepatitis C diagnostic ﬂowchart.p < 0.01). The anti-HCV prevalence increased with age: 0/131
(0.0%) in patients aged 30 years, 4/319 (1.3%) in patients aged
30–49 years, and 6/99 (6.1%) in patients aged 50 years (p < 0.01).
HIV type was not associated with anti-HCV status; anti-HCV
prevalence among HIV-1-infected patients was 7/417 (1.7%),
among HIV-2-infected patients was 1/55 (1.8%), and among
HIV-1/2 dually infected patients was 2/104 (1.9%) (p = 1.00). In
the patient group aged 50 years, the anti-HCV prevalence among
HIV-1-infected patients was 4/46 (8.7%), among HIV-2-infected
patients was 2/40 (5.0%), and among dually infected patients was
0/13 (0.0%) (p = 0.48). Furthermore, in this patient group the anti-
HCV prevalence was 2/39 (5.1%) in men and 4/60 (6.7%) in women
(p = 0.75). There was no signiﬁcant difference in median CD4 cell
count when comparing anti-HCV-positive and negative patients
(269 vs. 287 cells/ml; p = 0.50).
Potential risk factors were investigated for association with
anti-HCV positivity (Table 2). In the multivariable analysis, HCV
remained signiﬁcantly associated with age 50 years with an odds
ratio of 7.7 (95% conﬁdence interval 2.1–28.4). Only one patient
reported previous intravenous drug use; this patient was anti-
HCV-negative.
3.4. Clinical presentation of HCV infection
To evaluate the clinical presentation of HCV-infected patients,
we compared patients with active HCV infection (HCV RNA-
positive) and patients without active HCV infection (anti-HCV- and
HCV RNA-negative). We did not include patients with hepatitis B
virus infection (HBsAg) in the analysis. No subjective symptoms or
objective signs were signiﬁcantly more prevalent among patients
with active HCV compared with patients without active HCV
infection (data not shown). None of the study participants were
icteric, had dilated abdominal veins, or gynaecomastia.
The only biochemical marker associated with chronic HCV
infection was elevated serum amylase (83.3% vs. 38.6%; p = 0.03).
Table 2
Univariable and multivariable analysis of hepatitis C risk factors
Risk factors of anti-HCV Logistic regression, anti-HCV odds ratio
Univariable analysis Multivariable analysis
OR (95% CI) p-Value OR (95% CI) p-Value
Never used condoms 5.6 (0.7–44.2) 0.11 - -
Previously used condoms 1.00 -
Not circumcised 9.0 (1.1–71.3) 0.04 5.1 (0.54–47.3) 0.16
Circumcised 1.00 1.00
Ethnic group Papel, Mancanha, Balanta, or Mandjako 8.41 (1.06–66.9) 0.04 3.96 (0.42–37.0) 0.23
Other ethnic group 1.00 1.00
Age 50 years 7.2 (2.0–26.0) <0.01 7.7 (2.1–28.4) <0.01
Age < 50 years 1.00 1.00
HCV, hepatitis C virus; OR, odds ratio; CI, conﬁdence interval.
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cytopenia, low albumin concentration, elevated creatinine, biliru-
bin, alkaline phosphatase, or elevated liver enzymes (alanine
aminotransferase (ALT) and aspartate aminotransferase (AST)).
Among patients with active HCV infection, 6/8 (75.0%) were on
ART compared to 296/568 (52.1%) (p = 0.20). One patient with
detectable HCV RNA had elevated ALT (37 IU/l) and AST (124 IU/l);
this patient had been treated with a combination of zidovudine,
lamivudine, and ritonavir-boosted indinavir for 2 years at inclusion
date. Another HIV-infected patient had ALT within the normal
range and slightly elevated AST (57 IU/l), but this patient did not
receive ART.
4. Discussion
We have conﬁrmed a low prevalence of hepatitis C in this region
among HIV-infected patients. HCV infection was clinically silent
and all patients were more than 30 years old, with the majority
aged over 50 years.
A number of patients in this study were initially tested anti-
HCV-positive using an ELISA-based chemiluminescence test, but
subsequent testing for HCV RNA and anti-HCV by INNO-LIA
revealed some of the initial tests to have been false-positive. Thus,
our study provides a clear status on the number of patients
exposed and chronically infected with HCV. Previous studies have
reported that ELISA-based tests may overestimate anti-HCV
prevalence in resource-limited settings.23,24 The reason for this
may be cross-reaction to antibodies against other pathogens such
as malaria and schistosomiasis.25,26 The validity of the conﬁrma-
tory testing constitutes a major strength in our study. In fact, only a
few Sub-Saharan studies have used molecular methods to
determine the prevalence of HCV.10 The tests used may, however,
not be widely available for routine HCV screening in settings such
as Guinea-Bissau.9
A major limitation of this study is the relatively small number of
patients tested positive for anti-HCV and HCV RNA. This decreased
the power to detect any characteristics associated with HCV
infection and thus the ability to infer cause and effect. For risk
factor analysis, the sample size should ideally have been much
larger. Furthermore, as patients were included from an HIV clinic in
the capital city Bissau, the prevalence of HCV in this study may not
reﬂect the status of the general population in Guinea-Bissau. In a
population-based survey among individuals aged 50 years
performed in Bissau, the investigators found a tendency to a
lower anti-HCV prevalence among those with HIV-2 infection
(2.5%) and HIV-1 infection (0.0%) compared with the HIV-
seronegative participants (5.1%; p = 0.07).5 The anti-HCV preva-
lence was higher in our study, which consisted of relatively
immunosuppressed HIV-infected patients and individuals within a
wider age span. Nonetheless, we found no association between a
low CD4 cell count and anti-HCV status. The anti-HCV prevalenceamong HIV-positive and negative individuals was similar in a
study of pregnant women in Abidjan, Ivory Coast27 and in a study
of hospitalized patients in Uganda.28
Hepatitis C prevalence among HIV-infected patients has
previously been reported from other West African settings by
testing for anti-HCV: Ivory Coast (1.2%),27 Gambia (1.2%),29
Senegal (1.6%),30 Ghana (3.6%),31 and Nigeria (3.8%).32 Further-
more, the proportion with active versus previous HCV infection in
our study was 8/10 (80%), similar to other studies,17 and we
conﬁrm the presence of HCV genotype 2 in West Africa in
accordance with other studies.5,27,29 In this perspective, the
prevalence of anti-HCV in our study was comparable to previous
West African studies.
A number of studies have attempted to address risk factors for
HCV infection in Sub-Saharan Africa, but still the transmission
routes are not clear.8 The aforementioned population-based
survey from Guinea-Bissau found HCV infection to be associated
with a history of having bought or sold sexual services and
increasing age. Thus, the authors suggested that HCV genotype
2 transmissions occur through sexual intercourse.5 As in the
survey, we found higher levels of HCV prevalence among patients
not circumcised and certain ethnic groups in the univariable
analysis, but this association was not signiﬁcant in the
multivariable analysis. Stratiﬁcation into ethnic groups was
based on linguistic and cultural similarities.6 Buying sexual
services was not a risk factor for HCV infection in our study.
Sexual transmission of HCV is considered a rare event but may
occur.7 Cumulative exposure with increasing age may explain
why HCV infection was found to be associated with increasing
age in our study.33 Another explanation for this association is a
cohort effect of patients infected many years ago. Studies
performed in other Sub-Saharan African countries have found
evidence to support the transmission of HCV during hospital
admission and through non-sterile needle injections of antipar-
asitic drugs during the colonial era.34,35
The majority (80%) of anti-HCV-positive patients in this study
were women. In the population-based survey from Bissau,5 gender
was not associated with HCV infection. A previous study has linked
HIV-2 infection to clitoridectomy,36 and similar routes could cause
HCV transmission among women, however our study did not ﬁnd a
signiﬁcant association between circumcision and HCV infection
(Table 2).
We found no symptoms or objective signs to be associated with
active HCV infection, which is similar to a study from Uganda.37
The only biochemical marker associated with HCV infection in our
study was elevated amylase, which is not speciﬁc for liver disease.
Overall, physical signs and liver transaminase are poor predictors
of chronic liver disease due to HCV infection and are mainly seen in
end-stage liver cirrhosis.38 From this, we may conclude that HCV
infection among HIV-infected patients in Guinea-Bissau is a silent
disease. To diagnose HCV infection, screening of all patients is
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and no conﬁrmatory HCV RNA test is available, making the
implications of HCV diagnosis less clear.39 In low-resource settings,
ART affecting the liver such as nevirapine is often used. Even
though HCV treatment may not be available in many low-resource
settings, knowledge of the patient’s HCV status may be used by the
clinician to guide decisions on ART in the co-infected patient.10
Furthermore, when initiating ART, concomitant HCV infection may
contribute to an immune reconstitution syndrome (IRIS), which
could be confused with drug toxicity.34 Clinicians may also
encourage patients to limit the use of any other substances that
could worsen liver disease including alcohol.15
Before sending patient blood samples to the laboratory for
CD4 cell count, the samples were labelled with the date and a
unique identiﬁcation number. As only the staff at the HIV clinic
and afﬁliated researchers had access to the database, the
samples were anonymized for laboratory staff and anyone else
handling the samples. We did not actively search for patients to
provide them with the results of the HCV tests. In the case where
a participant might want the result of their HCV test, the results
could be traced from a different database and communicated to
the patient.
In conclusion, in this study the prevalence of HCV infection was
comparable to that in other West African countries, and as reported
by several other studies, the prevalence was higher among
individuals aged 50 years. The transmission routes of HCV in
Guinea-Bissau remain unclear, and we recommend that future
studies investigate whether HCV prevalence is declining. Among
the HIV-infected patients in Guinea-Bissau, HCV infection is a
silent disease making screening tests necessary to diagnose co-
infection. Although HCV treatment is not available in many low-
resource settings, screening is recommended to gain knowledge
and guide clinicians in the choice of an appropriate ART regimen
for HIV co-infected patients.
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